Methylphenidate denied access to WHO’s list of essential medicines for the third time

Attention-deficit/hyperactivity disorder (ADHD) affects 3%–5% of children and about 2.5% of adults, though prevalence varies across regions. 1 The psychostimulant methylphenidate is widely used as first-line treatment in many health systems.2